Aclidinium bromide/formoterol

Aclidinium bromide/formoterol, sold under the brand names Duaklir and Brimica, is a fixed-dose combination medication for inhalation, used in the management of chronic obstructive pulmonary disease (COPD). It consists of aclidinium bromide, a long-acting muscarinic antagonist, and formoterol, a long-acting β2 agonist.[3][4]

Aclidinium bromide/formoterol
Combination of
Aclidinium bromideLong-acting muscarinic antagonist
FormoterolLong-acting β2 agonist
Clinical data
Trade namesBrimica Genuair, Duaklir Genuair, Duaklir Pressair
AHFS/Drugs.comProfessional Drug Facts
License data
Pregnancy
category
  • AU: B3
Routes of
administration		Inhalation
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only) [1]
  • US: ℞-only [2]
  • EU: Rx-only [3][4]
  • In general: ℞ (Prescription only)
Identifiers
KEGG

References
  1. "Duaklir Genuair 340 micrograms /12 micrograms inhalation powder - Summary of Product Characteristics (SmPC)". (emc). 9 September 2019. Retrieved 26 July 2020.
  2. "Duaklir Pressair- aclidinium bromide and formoterol fumarte powder, metered". DailyMed. 3 July 2020. Retrieved 28 November 2020.
  3. "Duaklir Genuair EPAR". European Medicines Agency (EMA). Retrieved 26 July 2020.
  4. "Brimica Genuair EPAR". European Medicines Agency (EMA). Retrieved 26 July 2020.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.